Phase III Topical Application of Cocaine HCl 4% Solution on Safety/Efficacy & Cocaine HCl 4% & 10% Solution on Safety in Local Anesthesia for Diagnostic Procedures & Surgeries on or Through Accessible Mucous Membranes of the Nasal Cavities

Trial Profile

Phase III Topical Application of Cocaine HCl 4% Solution on Safety/Efficacy & Cocaine HCl 4% & 10% Solution on Safety in Local Anesthesia for Diagnostic Procedures & Surgeries on or Through Accessible Mucous Membranes of the Nasal Cavities

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Dec 2017

At a glance

  • Drugs Cocaine (Primary)
  • Indications Intraoperative pain; Procedural pain
  • Focus Registrational; Therapeutic Use
  • Sponsors Lannett
  • Most Recent Events

    • 01 Dec 2017 According to a Lannett media release, this FDA acceptance is based, on the data of this trial and other phase III trial (227076) along with the data of a pharmacokinetic phase 1 trial.
    • 01 Dec 2017 According to a Lannett media release, the U.S. Food and Drug Administration (FDA) has accepted a 505(b)(2) New Drug Application (NDA) filing for Cocaine Hydrochloride (HCl) Topical Solution, 4% and 10%, with a proposed trade name of Numbrino™, for the introduction of local (topical) anesthesia for diagnostic procedures and surgeries on or through the accessible mucous membranes of the nasal cavities. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of July 21, 2018.
    • 25 Sep 2017 According to a Lannett media release, the comapny has filled a 505(b)(2) New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for Cocaine Hydrochloride (HCl) Topical Solution with a proposed indication for the introduction of local (topical) anesthesia for diagnostic procedures and surgeries on or through the accessible mucous membranes of the nasal cavities.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top